Overview
Bronchitol (mannitol) is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years and older with Cystic Fibrosis.

Coverage Guidelines
Authorization may be granted for members new to AllWays Health Partners who are currently receiving treatment with Bronchitol, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:
1. Member has a diagnosis of Cystic Fibrosis.
2. The member has passed the Bronchitol Tolerance Test and did not experience any of the following during the test:
   a. Bronchospasm
   b. Decrease in FEV1
   c. Decrease in oxygen saturation
3. The member is at least 18 years of age.

Continuation of Therapy
Reauthorization may be granted for members when documentation is submitted supporting benefit from therapy as evidenced by disease stability or disease improvement (e.g., improvement in FEV1 from baseline).
**Limitations**
1. Initial approvals and reauthorizations will be for 24 months.
2. The following quantity limits apply:

| Bronchitol 40mg capsules | 600 capsules per 30 days |

**References**

**Review History**
05/19/2021 – Created and Reviewed May P&T. Effective 07/01/2021.

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.